Metabolic and endocrine is a focused but strategically loaded therapeutic area in Brazil. Samba Trials' Q2 2026 scan identified 21 industry-sponsored, actively-recruiting metabolic trials — 3.6% of the 582-trial national footprint. The number looks small next to oncology (250) or cardiovascular (35), but the sponsor mix and the patient-population math make it a high-signal area for biotech sponsors in obesity, type-2 diabetes, MASH/NASH, and rare endocrine disorders.
Brazil matters for metabolic R&D for two reasons most pipeline decks miss: the country has one of the largest obesity and T2D patient populations outside the U.S. and China, and its academic endocrinology centers sit inside major SUS referral networks that concentrate patients efficiently. If your protocol needs 500+ obese patients with documented cardiovascular risk factors enrolled inside 18 months, Brazil is one of the places that will actually deliver.
Why Brazil for metabolic and endocrine trials
- Patient population scale. Brazil has ~25% adult obesity prevalence and ~10% diagnosed T2D — and because SUS operates as a universal-access system, most of those patients are already on a documented care pathway through a named ambulatório. That makes recruitment dramatically faster than geographies where eligible patients are fragmented across private providers.
- Endocrinology-strong academic centers. Hospital de Clínicas de Porto Alegre (HCPA), Hospital das Clínicas da USP (São Paulo), Hospital das Clínicas de Ribeirão Preto, and the UNIFESP endocrinology service all run dedicated metabolic research units with PIs who have multi-sponsor trial experience going back 20+ years.
- Phase-3-friendly infrastructure. 60% of Brazil's industry trials are Phase 3 overall (351 of 582). For metabolic programs — which are almost always registration-enabling Phase 3 with cardiovascular-outcome or composite endpoints — Brazil's site capacity is well-suited and the GCP quality is on par with European-site deliverables.
- Cardiometabolic population genetics. Brazil's admixed population (Iberian, African, Indigenous, Japanese, and other European ancestries) provides genetic diversity that matters for sponsors running pharmacogenomic substudies or generalizability arguments to non-European regulators.
Where metabolic trials run
Unlike oncology (which clusters at Barretos and HCPA) or rheumatology (HCPA-dominant), metabolic trials in Brazil are distributed across academic-endocrinology services in the south and southeast. A typical metabolic Phase 3 activation in Brazil will combine an HCPA arm, a USP arm (São Paulo or Ribeirão Preto), and one or two private-investigator sites like Hospital Moinhos de Vento or CEPIC.
| Center | City / State | Role for metabolic trials |
|---|---|---|
| Hospital de Clínicas de Porto Alegre (HCPA) | Porto Alegre, RS | 53 active industry trials overall; strong endocrinology service with T2D, obesity, and rare-endocrine trial track record. |
| Hospital São Lucas da PUCRS | Porto Alegre, RS | 30 trials; cardiometabolic and endocrinology investigators experienced with multinational Phase 3 programs. |
| Hospital Moinhos de Vento | Porto Alegre, RS | 22 trials; private-hospital research unit often paired with HCPA for faster activation on the same protocol. |
| CEPIC — Centro Paulista de Investigação Clínica | São Paulo, SP | 14 trials; dedicated clinical-research center with strong metabolic and cardiovascular recruitment record. |
| Hospital Alemão Oswaldo Cruz | São Paulo, SP | 20 trials; private-academic hybrid; used by multiple Lilly / Novo Nordisk / AstraZeneca metabolic programs historically. |
| Fundação Faculdade Regional de Medicina de São José do Rio Preto (FAMERP) | São José do Rio Preto, SP | 35 trials; high-volume center in SP state interior with strong cardiometabolic enrollment. |
São Paulo state holds 252 of Brazil's 582 trials — including the São Paulo metro (454 trial-site records) and feeder cities like Campinas (86), Ribeirão Preto (78), and Santo André (65). Rio Grande do Sul (189) and Paraná (93) are the next-largest pools and over-index on metabolic research specifically because of HCPA and the UFPR endocrinology group.
Who's sponsoring metabolic trials in Brazil
Three of Brazil's top-25 sponsors have metabolic programs in the country with meaningful footprint: Eli Lilly and Company (28 total active Brazilian trials), Novo Nordisk A/S (5), and AstraZeneca (67 — oncology-tilted, but with a significant Forxiga and cardiovascular-outcomes presence). Sanofi (21 total trials, historical insulin and endocrine franchises), Boehringer Ingelheim (15 — SGLT2 and cardio-renal), and Novartis (33) round out a group that has been active in Brazilian metabolic R&D for a decade-plus.
Honest framing: 21 metabolic trials total means individual sponsor counts in this TA are small — anywhere from 1 to 5 per sponsor. We don't publish sponsor-by-TA granular counts in the free data; the number above are aggregate active-trial counts across all TAs. For TA-specific sponsor rankings (e.g., "which biotechs are running MASH trials in Brazil right now") see the full quarterly landscape report.
Emerging-biotech opening
25% of Brazilian industry trials (148 of 582) come from emerging-biotech sponsors — not big pharma. For a metabolic-focused biotech — say, a next-gen GLP-1/GIP agent, an oral amylin analogue, or a PNPLA3-targeted MASH therapeutic — Brazil is not yet saturated at the sponsor level. Being the second or third emerging biotech at HCPA on your mechanism is a meaningful site-relationship advantage.
Regulatory path: metabolic-specific considerations
Brazilian regulation runs in three parallel tracks: CEP (local site ethics), CONEP (central ethics review, required for international and certain study types), and ANVISA (the drug-specific clinical-trial dossier). Historical end-to-end timelines ran 9-12 months for a first-in-country protocol; under Lei 14.874/2024 the target is a ~6-month pathway, and we're seeing well-run submissions activate inside 6-8 months in practice.
For metabolic trials specifically, plan for:
- CONEP review on most international multicentric protocols. Metabolic trials almost always qualify (international sponsor, multi-country design), which adds a central review layer on top of local CEP.
- SUS-access statements for comparator drugs. If your protocol uses an active comparator (e.g., semaglutide, empagliflozin), ANVISA and CONEP reviewers will ask how trial participants access the comparator post-study — a detail that can slow approval when not addressed up front.
- Cardiovascular-outcome trial (CVOT) submethodologies. If you have event-driven cardiovascular endpoints, plan for an independent event-adjudication committee with at least one Brazilian cardiologist member — a de facto expectation.
How Samba Trials helps
Samba Trials is the medical-affairs and clinical-trials consultancy arm of BioAlma. We are not a CRO. Sponsors typically engage us before CRO selection, during feasibility, and through site activation:
- TA-specific feasibility memos. A 2-3 week review of your protocol synopsis against Brazilian metabolic-site capacity, competing-trial overlap (important when GLP-1 and SGLT2 protocols queue at the same sites), SUS comparator access, and realistic enrollment timelines by region.
- Site identification and activation support. Named-center shortlists with PI profiles, active-trial load, and historical sponsor relationships. We coordinate initial contact and scope conversations so your CRO arrives at an already-warm site.
- ANVISA submission strategy. Parallel-track planning for CEP/CONEP/ANVISA, dossier review against current reviewer expectations, and liaison with local regulatory consultants on metabolic-specific questions (SUS comparator access, biospecimen exports for PK/PD).
Get a metabolic feasibility memo
Send us your protocol synopsis or target indication. We'll return a Brazil-specific feasibility memo within two weeks, with named centers, PI candidates, and enrollment-timeline ranges.
Request a memo →